Zeltia, S.A.

Founded more than 70 years since its origin Zeltia group has been involved in the biopharmaceutical and chemical. Zeltia publicly traded since 1963 and in the continuous market since 1998.

The holding is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer
care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer’s disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

Website:
www.zeltia.com
Organisation Type
Ms MarĂ­a Herreras
Project Coordination Dept. 
Area of Interest

ZEW

Organisation Type
Dr Daniela Heimberger
Area of Interest